comprehensive -WSS

comprehensive

author：focus 2025-10-04 04:01:45 - browse：5212

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Watch the official trailer for 'Ahsoka' series

WSS

Inflation cooled significantly in June, bringing price hikes close to normal levels

STAT Summit: How a Chicago ER doctor tackles gun violence

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Why health workers in Gaza are injured or die at high rates

UnitedHealth’s board chair also owns a personal investment firm

FDA struggles to regulate food additives, sometimes for decades

leisure time

comprehensive

focus

What does generative AI mean for health care? We asked experts

STAT Summit: Biotech founders on deal

Tori Bowie and the unacceptable rates of Black maternal death

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Drug repurposing or repositioning? The language matters

Antibody drugs appear effective. Now can we make enough of them?

Alkermes shareholders re

Eli Lilly expects to double planned employment in Boston center

How to save PrEP access — and even expand it

The EU Joint Clinical Assessment needs to live up to its promise

hotspot

Beam Therapeutics to lay off 20% of its staff, re

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Eli Lilly expects to double planned employment in Boston center

STAT Summit: Michael J. Fox on progress in Parkinson's research

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

Digital health funding stays low as a new reality sets in

focus

focus

focus

explore